Observational multicentre study into the use of antiepileptic drugs in Spanish neurology consultations

Cerdá, J.M. Mercadé; González, Francisco Sánchez-Montes; Castro, Paulina; Vilanova, María Dolores Castro; Blanco, Dagoberto Mariño; Pascual, Manuel Rodríguez

doi:10.1016/j.nrleng.2018.01.009

Cited by 3 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epilepsy management in older patients should consider a range of factors linked to the efficacy and safety outcomes of ASMs in this context ( 17 ), including diagnosed epileptic syndrome, patient sex, comorbidities, concomitant medications, tolerability, and safety of ASM, while ensuring compatibility with local guidelines. Similarly, the decision to increase or decrease the doses of ASM should be guided by these factors to reflect an individualized assessment process ( 18 , 19 ), which also denotes that patient age also plays a significant role in influencing health outcomes during the ASM treatment process ( 20 , 21 ).…”

Section: Discussionmentioning

confidence: 99%

Effect of clinical features on antiseizure medication doses in patients with newly diagnosed epilepsy

Hersi,

Peltola,

Raitanen

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

ObjectiveWe evaluate the effect of distinct clinical features on anti-seizure medication (ASM) doses in seizure-free and not seizure-free patients aged ≥16 years with new-onset epilepsy.Materials and methodsThis study included 459 patients with a validated diagnosis of epilepsy. The most prescribed ASMs were oxcarbazepine (OXC; n = 307), followed by valproic acid (VPA; n = 115), carbamazepine (CBZ; n = 81), and lamotrigine (LTG; n = 67). The seizure freedom rate with their first or subsequent ASM was 88.0%. A retrospective analysis of patient records was performed to determine any association between doses of ASMs and patient characteristics.ResultsThe median OXC dose in seizure-free patients aged >60 years was 600 mg compared to 900 mg in younger patients. When controlling for age but not in an unadjusted model, the median dose of OXC was lower (300 mg, p = 0.018) for seizure-free patients compared to non-seizure-free patients, and the median dose of OXC was also 300 mg lower among older patients aged >60 years (p < 0.001). The median OXC doses for men aged ≤60 years were 300 mg higher than for women aged >60 years (900 mg vs. 600 mg, p = 0.021). The median dose of VPA was 400 mg higher in men than in women (p < 0.001) and 400 mg higher in not seizure-free patients compared to seizure-free patients only when adjusting for sex (p < 0.001). Higher median doses for CBZ were registered with FAS compared with FBTCS (difference in median doses of 200 mg; p = 0.017).ConclusionSignificant OXC dose differences were detected between age groups, whereas VPA dosing was different in men and women. Moreover, CBZ doses were dependent on some seizure types. These data allow for the individualization of the initial target dosing based on key clinical characteristics.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of clinical features on antiseizure medication doses in patients with newly diagnosed epilepsy

Hersi,

Peltola,

Raitanen

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…The disease can occur at any age and affects 1% of the human population worldwide [3]. Despite over 20 antiepileptic drugs being available, seizures remain uncontrolled in about 30% of patients [4] that can be related with the complex and multifactorial nature of epilepsy and its heterogeneity [5][6][7][8]. Viral infections of the CNS are among major risk factors for development of epilepsy [9].…”

Section: Introductionmentioning

confidence: 99%

Persistent Roseoloviruses Infection in Adult Patients with Epilepsy

et al. 2020

View full text Add to dashboard Cite

Background: Human herpesviruses (HHV)-6A, HHV-6B and HHV-7 are considered to be involved in the pathogenesis of epilepsy, a common neurological disorder. The objective of this study was to determine the association of roseoloviruses infection with epilepsy. Methods: 53 epilepsy patients and 104 ordinary blood donors were analyzed to determine presence of virus-specific antibodies by enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assay (IFA), genomic sequences, viral load and gene expression by polymerase chain reactions (PCRs) and restriction analysis, HHV-6 protein expression by IFA and level of cytokines by ELISA. Results: Roseoloviruses genomic sequences in DNA samples from whole blood were found in 86.8% of patients versus 54.8% of controls and active infection was revealed only in patients with epilepsy (19.6% of roseolovirus-positive patients). Significantly higher viral load and more frequent gene expression was detected in patients compared to the controls. HHV-6-encoded protein expression was demonstrated in 53.3% of patients with previously detected HHV-6 DNA. Changes in level of cytokines were determined in patients with elevated viral load compared to the patients without elevated viral loads and to the controls. Conclusions: Results on frequent active HHV-6 and HHV-7 infection in epilepsy patient’ peripheral blood indicate on possible involvement of these viruses in the disease development.

show abstract

Guidance for interactions between antiseizure medications

Antanasković

Janković

2023

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Observational multicentre study into the use of antiepileptic drugs in Spanish neurology consultations

Cited by 3 publications

References 50 publications

Effect of clinical features on antiseizure medication doses in patients with newly diagnosed epilepsy

Effect of clinical features on antiseizure medication doses in patients with newly diagnosed epilepsy

Persistent Roseoloviruses Infection in Adult Patients with Epilepsy

Guidance for interactions between antiseizure medications

Contact Info

Product

Resources

About